{{Rsnum
|rsid=7787082
|Gene=ABCB1
|Chromosome=7
|position=87527735
|Orientation=plus
|GMAF=0.3678
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=ABCB1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 1.5 | 32.3 | 66.2
| HCB | 25.9 | 52.6 | 21.5
| JPT | 15.5 | 57.3 | 27.3
| YRI | 47.6 | 44.2 | 8.2
| ASW | 36.8 | 42.1 | 21.1
| CHB | 25.9 | 52.6 | 21.5
| CHD | 19.6 | 49.5 | 30.8
| GIH | 5.0 | 38.0 | 57.0
| LWK | 47.7 | 42.1 | 10.3
| MEX | 0.0 | 0.0 | 0.0
| MKK | 37.8 | 47.4 | 14.7
| TSI | 3.0 | 36.4 | 60.6
| HapMapRevision=28
}}[[rs7787082]] is a SNP in the [[ABCB1]] gene (also known as the MDR1 gene), which encodes a protein that transports certain molecules across the blood-brain barrier. SNPs in [[ABCB1]] may thus influence the intracerebral concentrations of certain drugs and thus their efficacy or potential for adverse side effects. [[rs7787082]] is one of 9 SNPs found within a tight linkage block (r<sup>2</sup> >= 0.8 ) such that the minor allele at any one of them predicts (with ~80%+ accuracy) that the other SNPs will also be the minor allele. The list of the 9 SNPs is shown below.

When treated for [[depression]] with substrates of the protein encoded by [[ABCB1]], carriers of one or two minor alleles at these [[ABCB1]] SNPs have been reported to respond better than non-carriers. The [[antidepressant]] drugs that are known to be substrates include [[citalopram]], [[paroxetine]], [[amitriptyline]], and [[venlafaxine]]. The relative odds of better response for [[rs7787082]](G) carriers is 7.72 (CI: 2.8-21.3, p=0.000065) based on a study of ~400 primarily Caucasian patients.{{doi|10.1016/j.neuron.2007.11.017}}

The 9 SNPs in the linkage block identified are {{doi|10.1016/j.neuron.2007.11.017}}:
* [[rs2235067]]
* [[rs4148740]]
* [[rs2032583]]
* [[rs4148739]]
* [[rs11983225]]
* [[rs2235040]]
* [[rs12720067]]
* [[rs7787082]]
* [[rs10248420]]

{{PharmGKB
|RSID=rs7787082
|Name_s=
|Gene_s=ABCB1
|Feature=
|Evidence=PubMed ID:18215618
|Annotation=This variant is associated with differences in clinical efficacy of antidepressants, most likely by influencing their access to the brain.
|Drugs=amitriptyline; citalopram; paroxetine; venlafaxine
|Drug Classes=
|Diseases=Depression
|Curation Level=Curated
|PharmGKB Accession ID=PA161615695
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs7787082
|overall_frequency_n=45
|overall_frequency_d=128
|overall_frequency=0.351562
|n_genomes=27
|n_genomes_annotated=0
|n_haplomes=40
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=22722500
|Title=Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response.
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | Illumina Human 1M}}